RenovoRx, Inc.RNXT

$0.92+0.03 (+3.29%)

NASDAQHealthcare24:00 UTC

Company snapshot

Market Cap

$35M

Micro-cap

-71%

2021 — today

10-Year Price

-87%

2021 — today

52-Week Range

$0.73$1.42

Current $0.92· 27%

RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.

Valuation in context

P/E ratio

-2.7

N/A

Not meaningful — company is unprofitable

P/B ratio

3.1

Below average

Below the 10-year average

FCF Yield

-32.3%

Below average

Below the 10-year average

Free · No credit card needed

Get alerted when RNXT is cheap

Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.